1. The role of metabolic reprogramming in pancreatic cancer chemoresistance
   Chang Liu et al, 2023, Frontiers in Pharmacology CrossRef
2. Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals
   Xianhui Liu et al, 2024, Journal of Biological Chemistry CrossRef
3. Structure–activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling
   Ahmed Abdullah Ahmed et al, 2024, Scientific Reports CrossRef
4. Stomatin-like protein 2 deficiency exacerbates adverse cardiac remodeling
   Yuntao Hu et al, 2023, Cell Death Discovery CrossRef
5. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib
   Yufeng Liu et al, 2023, Oncogene CrossRef
6. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer
   Hui-Ru Zhang et al, 2024, Cell Death & Disease CrossRef
7. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation
   Cheng Qin et al, 2023, Cell Death & Disease CrossRef
8. The Hexosamine Biosynthesis Pathway: Regulation and Function
   Alysta Paneque et al, 2023, Genes CrossRef
9. Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) Is Upregulated in Breast Epithelial–Mesenchymal Transition and Responds to Oxidative Stress
   Qiong Wang et al, 2022, Molecular & Cellular Proteomics CrossRef